On the clinical side, several epidemiological studies have examined the risk of prostate cancer in BRCA1 and BRCA2 mutation carriers, and BRCA2 mutations increase the risk of prostate cancer in what appears to be a more progressive manner, whereas the effects of mutations in the BRCA1 gene appear to be more modest (3, 5). This evidence concerns the gene BRCA2 and prostate cancer.